ABSTRACT -To attempt a risk assessment of the excess intake of trivalent chromium (Cr), tissue Cr accumulation and urinary Cr excretion were examined in weanling rats fed experimental diets containing graded levels of Cr chloride (CrCl 3 ) or Cr picolinate (CrPic). Thirty-six male weanling 4-weeks-old Wistar rats were divided into six groups and fed a casein-based semi-purified diet (Cr content: < 0.02 μg/g) supplemented with 1, 10, or 100 μg Cr/g as CrCl 3 or CrPic for 28 days. Among the experimental groups, no significant difference was observed in body weight; however, supplementation of 100 μg Cr/g to the diets caused a significant low liver weight irrespective of the chemical species of Cr. Activities of serum aspartate aminotransferase and alanine aminotransferase were significantly elevated in rats given CrPic at 100 μg Cr/g. In the liver, kidney and femur, Cr accumulation increased with elevation of the dietary Cr level. No influence of the difference in the chemical species of supplemented Cr was observed in the liver and kidney, but CrCl 3 caused significantly higher Cr accumulation than CrPic in the femur of rats given 100 μg Cr/g. Daily urinary Cr excretion elevated with the increase of the dietary Cr level. Rats given CrPic showed significantly higher daily urinary Cr excretion than those given CrCl 3 , particularly at a dietary Cr level of 100 μg/g. The rate of urinary Cr excretion in rats given CrPic was constant, irrespective of the dietary Cr level, but that of rats given CrCl 3 fell with the increase of the dietary Cr level. These results indicate that the lowest adverse effect level of dietary Cr is less than 100 μg/g, irrespective of the chemical species of Cr.
INTRODUCTION
Trivalent chromium (Cr) is an essential trace element for human and animal nutrition (Mertz, 1993) and enhances insulin function in the form of a low molecular weight Cr binding substance (LMWCr), called chromodulin (Vincent, 2004) . Severe Cr deficiency induces impaired glucose tolerance and is believed to increase the risk for diabetes (Mertz, 1969) . Since a high dose (200 to 1,000 μg/day) of Cr improved glycemia among patients with diabetes (Lamson and Plaza, 2002; Rabinovitz, 2004) , some healthy people take a Cr supplement, expecting an improvement of lipid or glucose metabolism. Cr chloride (CrCl 3 ), Cr nicotinate, and Cr picolinate (CrPic) are used as formulations of trivalent Cr. Among these, CrPic is designed to improve absorption (Evans and Pouchnik, 1993) and is the most common Cr supplement. In the U.S., manufactures and sellers of Cr supplements ardently promote the benefits of Cr in the prevention and treatment of type 2 diabetes, dyslipidemia, and cardiovascular disease. As a result, estimated sales of Cr supplements to consumers were about $150 million in 2008, exceeding those of calcium supplements (Nutrition Business Journal, 2009) . In spite of the general public's acceptance of Cr supplements, the scientific basis of the protective efficacy of Cr against disease, including diabetes, is weak. In a systematic review of the effect of Cr supplementation at 200 to 1,000 μg/day on glucose metabolism and lipid levels, it was concluded that no significant effect of Cr on lipid or glucose metabolism was found in people without diabetes (Balk et al., 2007) . In contrast, excess intake of trivalent Cr can possibly have adverse effects on humans and animals. In fact, several case reports pointed out the occurrence of adverse effects, including anemia, liver and kidney dysfunctions, or muscle cramps due to the ingestion of CrPic at 200 to 1,000 μg Cr/day (Wasser, 1997; Martin and Fuller, 1998; Wani et al., 2006) . However, the possibility that other supplements or drugs ingested concomitantly are associated with these symptoms cannot be excluded in these cases and there are no available data giving clear information on the dose-response relationship between Cr and its adverse effects. Due to limited human data on the toxicity of trivalent Cr, many devel- The Cr intake of Japanese adults was estimated to be about 120 μg/day (Otsuka et al., 2000) . Since this estimated value far exceeds 25 to 40 μg/day, which is the recommended dietary allowance of Cr for Japanese adults (Ministry of Health, Labour and Welfare of Japan, 2009), the possibility of dietary Cr deficiency in the general Japanese is extremely low. Thus, it is thought that the use of Cr supplements does not have benefits but rather adverse effects on healthy Japanese. In the present study, we examined urinary Cr excretion and Cr accumulation in the organs of weanling rats fed experimental diets containing graded levels of CrCl 3 or CrPic and attempted a risk assessment of the excess intake of trivalent Cr.
MATERIALS AND METHODS

Reagents
CrCl 3 (Cr (III) chloride hexahydrate) was purchased from Nacalai Tesque (Kyoto, Japan). CrPic (Cr (III) picolinate) was purchased from Tokyo Chemical Industry (Tokyo, Japan). The ingredients of animal diets were purchased from Oriental Yeast Co. (Tokyo, Japan). Cr standard solution (1,000 μg Cr/ml as K 2 Cr 2 O 7 in 0.1 M HNO 3 ), rhodium (Rh) standard (1,000 μg Rh/ml of as Rh(NO 3 ) 2 in 2 M HNO 3 ), distilled water (HPLC grade), and metal-free grade HNO 3 were purchased from Wako Pure Chemical Industries (Osaka, Japan).
Animal experiments
The experimental protocol was reviewed and approved by the Animal Ethics Committee of Kansai Medical University and followed the "Guide for the Care and Use of Experimental Animals" of the Prime Minister's Office of Japan. Experimental animals were fed in a room under a controlled 12 hr light (8:00 to 20:00) and dark cycle at a temperature of 23 to 24˚C and humidity of 60%. The animals were given experimental diets and deionized water ad libitum during the entire experimental period.
Thirty-six male weanling 4-weeks-old Wistar rats were divided into six groups and fed a casein-based semi-purified basal diet (Cr content: < 0.02 μg/g) supplemented with 1, 10, or 100 μg/g of Cr as CrCl 3 or CrPic. The basal diet excluded CrCl 3 from the AIN93G diet (Reeves et al., 1993) . On the 23rd to 26th day after the start of feeding, urine samples were collected from all rats. After feeding for 28 days, the rats were anesthetized with sodium pentobarbital, blood was collected from the abdominal aorta, and the liver, kidney and femur were excised, washed with saline, blotted and weighed.
A part of each blood sample was transferred to a heparinized tube and subjected to hemoglobin determination. Serum was separated from the remainder of the blood and subjected to serum biochemical tests (total protein, albumin, triglyceride, total cholesterol, glucose, urea, iron, creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT)). The hemoglobin measurement and serum biochemical tests were performed by a commercial service system (Japan Medical Laboratory, Osaka, Japan).
Analysis of Cr
Cr in the organ and urine samples was determined by inductively coupled plasma mass spectrometry (ICPMS) using Rh as an internal standard. Up to 1 g of the liver, kidney or femur was heated with 5 ml of metal-free HNO 3 in a boiling water bath until the disappearance of insoluble components. The volume of the digest was made up to 25 ml with distilled water. One milliliters of urine was diluted with 9 ml of 0.1 M HNO 3 . Cr in the diluted digest and urine was directly nebulized to ICPMS. Details of the ICPMS operating condition for Cr determination were described previously (Yoshida et al., 2008) .
Histopathology
Liver samples were sectioned and the blocks obtained Vol. 35 No. 4 were fixed in 4% formaldehyde. Tissues were embedded in paraffin, sectioned at a thickness of 5 μm, and stained with hematoxylin and eosin. A pathologist without knowledge of the animal treatment evaluated the sections.
Statistics
Experimental data were assessed by two-way analysis of variance (ANOVA). When the F value was significant (p < 0.05) in the Cr level, the Scheffe multiple range test was performed to determine which pairs of the Cr levels were significantly different (p < 0.05). In addition, when the F value was significant (p < 0.05) in the interaction between the Cr level and Cr species, the Scheffe multiple range test was performed to determine which pairs of the means were significantly different (p < 0.05). These statistical tests were performed using a personal computer (eMac; Apple Computer, Cupertino, CA, USA) with operating system Mac OS 9.2 and statistical program package StatView-J version 5.0 (Abacus Concept, Berkeley, CA, USA). Table 1 shows the body, liver and kidney weights of rats fed experimental diets containing 1 to 100 μg/g of Cr as CrCl 3 or CrPic for 28 days. Among the experimental groups, no significant difference was observed in the body weight; however, supplementation of 100 μg Cr/g to the diets caused a significantly lower liver weight. In the kidney weight, rats fed diet containing 100 μg Cr/g as CrPic tended to show lower values compared to other groups of rats. Table 2 shows serum AST and ALT activities in rats fed experimental diets. Dietary supplementation with CrPic at a level of 100 μg Cr/g significantly elevated these serum transaminase activities. In spite of the elevation of AST and ALT activities, no hepatic histopathological changes were observed even in rats fed a diet containing CrPic at 100 μg Cr/g. No significant difference was observed among experimental groups in the hemoglobin level and serum biochemical tests, except for transaminase activities. Table 3 summarizes Cr concentration in the liver, kidney and femur. In all organs examined, Cr accumulation increased dependently on the dietary Cr level. No influence of differences in the chemical form of supplemented Cr was observed in the liver and kidney, but was manifested in the femur; CrCl 3 caused significantly higher Cr accumulation than CrPic in the femur of rats fed diets containing 100 μg Cr/g. Table 4 shows the urinary Cr excretion of rats fed the experimental diets. Daily urinary Cr excretion elevated with the increase of the dietary Cr level. Differences in the chemical form of dietary Cr marked influenced urinary Cr excretion. Rats given CrPic showed significantly higher daily urinary Cr excretion than those given CrCl 3 , particularly at a dietary Cr level of 100 μg/g. In rats given CrPic, the rate of urinary Cr excretion was constant (1.36 to 1.52%) irrespective of the dietary Cr level. On the other hand, the rate of urinary excretion fell with increased dietary Cr in rats given CrCl 3 .
RESULTS
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DISCUSSION
In the present study, dietary Cr supplementation decreased liver weight at 100 μg/g, irrespective of the chemical species. Since a difference between CrCl 3 -and CrPic-loading was not observed in the hepatic Cr accumulation, the decrease must be associated with the accumulated Cr. Because no histopathological changes were detected, the decrease may not be a disease change. Nevertheless, it can be said that trivalent Cr inhibits liver growth.
In addition to the lowered liver weight, rats fed diets supplemented with CrPic at 100 μg Cr/g showed elevated serum transaminase activities. It has been reported that CrPic causes liver dysfunction in human and animals (Cerulli et al., 1998; Bagchi et al., 2002) , and picolinate induces apoptosis in several types of cultured cells (Ogata et al., 2000) . Thus, it can be concluded that CrPic impairs liver cells by a mechanism different from CrCl 3 .
Cr accumulation in the organs and urinary Cr excretion rose with increased dietary Cr and no difference with the chemical form of supplemented Cr was observed in hepatic and renal Cr accumulation. However, administration of CrPic caused lower femur Cr accumulation and higher urinary excretion than that of CrCl 3 at a dietary Cr level of 100 μg/g. On the other hand, while the rate of urinary Cr excretion of rats given CrPic was constant irrespective of the dietary Cr level, that of rats given CrCl 3 decreased with the increase of the dietary Cr level. In several organs, LMWCr is estimated to exist as the apo form (Yamamoto et al., 1987) . After the intake of a large dose of Cr, apoLMWCr probably binds to Cr and carries it into the urine (Wada et al., 1983) . Accordingly, the decreased urinary excretion rate of Cr in rats given large amounts of CrCl 3 indicates that excess Cr saturates the urinary Cr excretion process via LMWCr. Thus, not Cr absorption but Cr excretion is thought to be higher in rats given CrPic than given CrCl 3 . Picolinic acid increases urinary excretion as well as absorption of zinc and results in the increased turnover of endogenous zinc (Seal and Heaton, 1985) . Similarly to zinc, Cr excretion may have been accelerated by picolinate, resulting in low Cr accumulation in the femur. Anderson et al. (1997) observed no change of body, liver and kidney weights as well as serum biochemical tests, including transaminase activities in weanling rats fed diets supplemented with CrCl 3 or CrPic up to 100 μg Cr/g, and emphasized the lack of toxicity of trivalent Cr. In addition, they observed that rats consuming CrPic-supplemented diets had several-fold higher Cr concentrations in both the liver and kidney than those fed CrCl 3 and concluded that the absorption of CrPic was higher than CrCl 3. The reason for the inconsistency between the studies of Anderson et al. (1997) and ours could not be sufficiently 
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Vol. 35 No. 4 clarified. Differences between the two studies exist in the strain of rats, the feeding period and the basal diet used. Among these, differences in the basal diet may influence the manifestation of Cr toxicity and Cr metabolism. In the present study, we used a standard semi-purified diet, called AIN93G diet, as the basal diet. This diet is composed of purified casein and starch, sucrose, soybean oil, and mineral and vitamin mixtures (Reeves et al., 1993) . On the other hand, Anderson et al. (1997) used a commercial stock diet (RMH 3200, Agway Inc., Waverly, NY, USA). This diet is composed of non-purified feed materials, such as cereal and grass, and contains various fibers and flavonoids. Since these substances are known to inhibit the intestinal absorption of several kinds of metals (Hurrell et al., 1999; Sandberg, 2002; Zijp et al., 2000) and prevent liver impairment (Ibrahim et al., 2008; Park et al., 2008) , intake of the stock diet may have modified Cr absorption and CrPic-induced liver impairment. However, because raw materials and composition of these commercial stock diets including the RMH 3200 are not constant, it is impossible to evaluate Cr toxicity under the same condition as the Anderson's study. Nevertheless, it is necessary to examine the effect of difference in basal diet (stock diets or semi-purified diets) on the manifestation of Cr toxicity. A general human diet is not a semi-purified diet, but it is impossible to evaluate the effects of numerous unknown components contained in the human diets on Cr toxicity. Accordingly, due to the least unknown dietary factor, the results on Cr toxicity, tissue accumulation and urinary excretion obtained from our study using a semi-purified diet are available for a risk assessment of trivalent Cr. As for CrPic, since a dietary level of 100 μg Cr/g decreased the liver weight and elevated serum transaminase activities, the lowest observed adverse effect level (LOAEL) in the diet can be estimated to be below 100 μg Cr/g. Similarly, the LOAEL for dietary CrCl 3 was also below 100 μg Cr/g since saturation of the urinary Cr excretion process was observed at this dose level. Thus, it is concluded that the LOAEL for dietary Cr is less than 100 μg/g, irrespective of the chemical species of Cr. Since rats eat about 10% of their body weight every day, the dietary level of 100 μg/g corresponded to about 10 mg/kg. However, it is known that trivalent Cr shows mutagenicity or damages chromosomes in animal cells (Stearns et al., 1995; 2002) ; therefore, research extend over the second generation is necessary for the risk assessment of trivalent Cr.
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